← All trials
NCT06040541
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 7, 2023
- Primary completion
- Aug 30, 2025
- Completion date
- Jul 31, 2026
- First posted
- Sep 15, 2023
- Last posted
- Dec 18, 2023
- Enrollment
- 290
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Revolution Medicines, Inc.Lead sponsor
- Revolution Medicines, Inc.Study director
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.